Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1481-1500 of 3,900 trials

Hypertrophic Cardiomyopathy: Aficamten Study

We are evaluating the long-term safety and tolerability of aficamten in adults with hypertrophic cardiomyopathy. The study also looks at its effects on heart function in patients with obstructive HCM.

Hypertrophic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Autoimmune Disease: Ianalumab Delivery Methods

We are comparing two ways to deliver ianalumab to adults with autoimmune diseases. This study will help us understand how well the medication works and its safety when given in different forms.

Sjögren's DiseaseRheumatoid ArthritisSystemic Lupus Erythematosus6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

Cardiac Device Implantation: Local vs. Regional Anesthesia

We are comparing local anesthesia with a specific regional block to see which provides better comfort for patients undergoing cardiac device implantation. This study also looks at any side effects and the need for extra pain relief.

Implantation of Cardiac Devices1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology

Pancreatic Cancer: Antiplatelet Therapy Study

We are investigating if adding an antiplatelet medication to standard care can help prevent blood clots in patients with pancreatic cancer. We also want to see if it may improve survival rates.

Pancreatic Ductal Cancer6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyOncology

Graft-Versus-Host Disease Prevention: CY-MET-RIC Study

We are testing two different treatment plans to see which better prevents severe graft-versus-host disease in patients receiving matched-donor transplants. This study will also evaluate overall survival and other important health outcomes.

Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Vedolizumab for Children with Moderate to Severe Crohn's Disease

We are studying how well different doses of vedolizumab help children and teenagers with Crohn's disease maintain their health. The goal is to see if it can keep symptoms under control and improve their overall well-being.

Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterology

Advanced Solid Tumors: AMG 355 Treatment Study

We are exploring a new treatment called AMG 355, both alone and with Pembrolizumab, for individuals with advanced solid tumors. This study aims to assess its safety and potential effectiveness.

Malignant Solid Tumor>2 yearsSafety phase (I)Oncology

Ivosidenib for Acute Myeloid Leukemia After Stem Cell Transplant

We are studying whether Ivosidenib can help patients with acute myeloid leukemia or high-risk myelodysplastic neoplasia stay healthy after a stem cell transplant. This trial focuses on those with an IDH1 mutation to see if it improves their chances of remaining disease-free.

Acute Myeloid Leukemia (AML)Myelodysplastic Neoplasia (MDS)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Small Cell Lung Cancer: AL8326 Treatment Study

We are evaluating the safety and effectiveness of the drug AL8326 for patients with small cell lung cancer who have already received prior treatment. This study aims to find the best dose and understand how well the drug works.

Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Idiopathic Pulmonary Fibrosis: Buloxibutid Study

We are testing a new medication, buloxibutid, to see if it helps improve lung function and quality of life for people with idiopathic pulmonary fibrosis. The study compares its effects to a placebo over time.

Idiopathic Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Septic Shock: Early Use of Vasopressin

We are studying whether starting vasopressin treatment earlier helps improve kidney function in patients with septic shock. This trial aims to see if it reduces the need for kidney support and other complications in the ICU.

Septic Shock1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrologyPulmonology

Lung Cancer: Repotrectinib for Elderly Patients

We are studying the effectiveness of Repotrectinib in frail or elderly patients with advanced lung cancer. The trial aims to see if this treatment can improve tumor response and overall health.

Stage III/IV Non-Small-Cell Lung Cancer with ROS1 Rearrangement>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Metastatic Uveal Melanoma: Tebentafusp Treatment

We are studying the effects of tebentafusp in patients with metastatic uveal melanoma that has spread to the liver. The goal is to see if it can help achieve complete responses and improve disease control.

Uveal Melanoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Ovarian Stimulation for Poor Responders: CFA vs. Modified Natural Cycles

We are comparing a single cycle of a new medication with multiple natural cycles in women who may not respond well to fertility treatments. The goal is to see which method leads to better quality embryos and higher chances of pregnancy.

Subfertility3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Crohn's Disease: New Treatment Target Study

We are investigating if aiming for complete healing of all bowel layers improves outcomes for patients with active Crohn's disease. This study compares different treatment strategies to see which is more effective.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

TMJ Arthritis: Cortisone Injection vs. Arthrocentesis

We are comparing the effectiveness of a cortisone injection and a procedure called arthrocentesis for relieving pain in people with TMJ arthritis. We also want to see how these treatments affect mouth opening and if other factors play a role in recovery.

Temporomandibular Joint Arthritis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and Traumatology

Sotagliflozin for Post-Bariatric Hypoglycaemia

We are studying whether sotagliflozin can help people who have low blood sugar after weight loss surgery. Participants will receive either the medication or a placebo to compare effects on blood sugar levels.

Postbariatric Hypoglycemia≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyInternal Medicine

Atopic Dermatitis in Children: Abrocitinib Study

We are investigating the effectiveness and safety of Abrocitinib for children aged 6 to under 12 with moderate-to-severe atopic dermatitis. The study will compare it to a placebo while using other topical treatments.

Moderate-to-Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Primary Immune Thrombocytopenia: Belantamab Mafodotin Study

We are investigating a new treatment for adults with primary immune thrombocytopenia who have previously received other therapies. The study aims to assess the safety and effectiveness of this new drug.

Primary Immune Thrombocytopenia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematology